The Role for Consolidative Local Therapy in Stage IV Non-Small Cell Lung Cancer for Oligometastases and Beyond: How are We Improving Outcomes for Patients?
Patients with Stage IV Lung cancer vary in their response to the numerous systemic therapies and are living longer. The role of aggressive local therapy or metastatic directed therapy (MDT) is critical for radiation oncologists and surgeons.
Category
  • Oligometastatic
  • Thoracic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Oligometastatic Prostate Cancer: How Far Do We Go?
There have been many advancements in terms of treatment and imaging modalities for patients with oligometastatic prostate cancer. Failure to understand these advancements in treatment options leads to lower quality of care delivered by clinicians treating prostate cancer patients.
Category
  • Genitourinary
  • Oligometastatic
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Non-Operative Management in Rectal Cancer Contemporary Practice
Modern treatment options such as radiotherapy dose intensification (EBRT boost, brachytherapy or Papillon technique) or additional chemotherapy in total neoadjuvant therapy for rectal cancers have been shown to improve rectal preservation rates better than ever before.
Category
  • Brachytherapy
  • Gastrointestinal
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00
Mechanistic Insights and Knowledge Gaps in the Effects of Radiation Therapy on Cardiac Arrhythmias
This paper presents a review of the management of cardiac arrhythmias with radiation including the pathophysiology.
Category
  • Nonmalignant RT
  • Thoracic
Format
  • Journal Activities
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $49.00
Patient Reported Outcomes Following MR-guided Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis
In this activity participants will learn how MR-guided radiation therapy impacts patient-reported outcomes in patients with prostate cancer.
Category
  • Genitourinary
Format
  • Journal Activities
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $49.00
Clinical Applications of AI: Contouring and Patient-Specific QA
There are many advances in the application of artificial intelligence (AI) in contouring and segmentation, as well as patient specific quality assurance.
Category
  • Patient Safety
  • Physics
Format
  • Sessions onDemand
Credits
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Certificate of Attendance
  • 0.75 SA-CME
Cost $149.00
Central Nervous System - Refresher 2022
The course reviews the current clinical management of the most common malignant and benign adult CNS tumors. This review is be followed by an overview of the current clinical practice in the treatment of brain metastases.
Category
  • Central Nervous System
Format
  • Sessions onDemand
Credits
  • 1.50 Certificate of Attendance
  • 1.50 SA-CME
Cost $105.00
Challenging Cases in Palliative Care
With this activity, ASTRO continues its series of challenging case panel sessions related to palliative radiotherapy for patients with advanced cancer.
Category
  • Central Nervous System
  • Gastrointestinal
  • Palliative Care
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Palliative Re-Irradiation
Palliative radiotherapy (RT) is a foundation of the discipline and practically represents a significant portion of most practices. The standard protocols for palliative RT (8Gy x 1, 4Gy x 5, etc.) were pioneered almost 50 years ago, when systemic therapies were far less useful.
Category
  • Central Nervous System
  • Palliative Care
Format
  • Sessions onDemand
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Certificate of Attendance
Cost $149.00
Evolving Therapeutic Strategies in the Multidisciplinary Management of Patients with Hepatocellular Carcinoma – Improving Outcomes
The management of Hepatocellular Carcinoma (HCC) should be conducted in a multidisciplinary setting to offer individualized therapy. Most patients with HCC are not candidates for curative treatments because of tumor extent or underlying liver dysfunction.
Category
  • Gastrointestinal
  • SBRT
Format
  • Sessions onDemand
Credits
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Certificate of Attendance
Cost $149.00

Pages